Protein Expression and Codon 72 Polymorphism of TP53 Gene in Triple Negative Breast Cancer

Brazilian Archives of Biology and Technology

Leandra Fiori Lopes¹  Roberta Losi Guembarovski¹  Alda Losi Guembarovski¹  Marina Okuyama Kishima¹  Clodoaldo Zago Campos¹  Daniela Rudgeri Derossi¹  Carolina Batista Ariza¹  Patricia Midori Murobushi Ozawa¹  Carlos Eduardo Coral De Oliveira¹  Bruna Karina Banin-hirata¹  Glauco Akelinghton Freire Vitiello¹  Sueli Donizete Borelli¹  Maria Angelica Ehara Watanabe¹ 

关键词: breast cancer;    TNBC;    TP53;    genetic polymorphism;    immunohistochemistry;   

DOI  :  10.1590/S1516-8913201402559

来源: SciELO

【 摘 要 】

A subgroup of tumor that has received attention is triple-negative breast cancer (TNBC), which presents phenotype of negative estrogen receptor, negative progesterone receptor and has no overexpression of HER2. TP53 acts as a tumor suppressor limiting the proliferation of damaged cells. A polymorphic site (rs1042522) of TP53 encodes either an arginine or a proline amino acid, but its biological significance remains unclear. This study aimed to investigate this variant and its expression in search for a possible involvement in TNBC susceptibility and clinical outcome. Genetic polymorphism was evaluated in 50 patients and 115 controls by PCR based methodology and immunohistochemistry was done with monoclonal antibody. Case-control study showed no positive or negative association (OR= 0.95; CI95%= 0.48-1.89). Comparison of genotypes and clinical outcome showed no significant results. Despite most of patients presented p53 positive staining by immunohistochemistry, there was no significant association in relation to prognostic parameters. Results demonstrated a lack of association between codon 72 polymorphism, susceptibility and prognosis of TNBC. Immunohistochemistry analysis should be done more carefully, since most of the patients had the somatic mutation of p53, which could be an indicator of prognostic value in TNBC.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License